Indivior's Board Revamp: A Step Towards Strategic Growth

Indivior PLC, a global pharmaceutical company specializing in addiction treatment, has announced significant changes to its Board of Directors. These changes, effective as of March 4, 2025, aim to better align the company's capabilities and resources with its strategic priorities and enhance its commercial and R&D focus on high-value opportunities. The key appointments and changes include:

1. Appointment of Dr. David Wheadon as Chair: Dr. Wheadon brings extensive pharmaceutical and biotechnology industry experience to the role, having served in senior positions at AstraZeneca, Juvenile Diabetes Research Foundation, and Pharmaceutical Research and Manufacturers of America (PhRMA). His appointment was approved by shareholders at the 2025 Annual General Meeting (AGM), indicating support for his leadership.
2. Appointment of Daniel Ninivaggi as an Independent Non-Executive Director: Mr. Ninivaggi has a strong track record in the pharmaceutical industry, having served as CEO of Lantheus Holdings, Inc. and held various leadership roles at Covidien plc and Medtronic plc. His appointment was agreed upon following discussions with Oaktree Capital Management L.P., indicating that his expertise and experience align with the Company's strategic goals.
3. Appointment of Joe Ciaffoni as Chief Executive Officer (CEO): Mr. Ciaffoni is an accomplished public company CEO with over 30 years of experience in pharmaceuticals and biotech. His appointment was subject to the approval of a new remuneration policy at the Company's AGM in May 2025, indicating shareholder support for his leadership. As CEO, he is responsible for driving the Company's strategic direction, fueling its growth, and delivering on its significant potential.
4. Reduction in the size of the Board to seven directors: The Board's size was reduced to seven directors, with the departure of Peter Bains and Jo LeCouilliard. This change aligns with Indivior's strategic objective of maintaining a Board with an appropriate size and composition to effectively oversee the company's operations and make decisions.

These changes demonstrate Indivior's commitment to enhancing its governance, operational leadership, and alignment with shareholder interests, all of which are crucial for achieving its strategic objectives and long-term growth plans. The appointments of Dr. David Wheadon as Chair, Daniel Ninivaggi as an Independent Non-Executive Director, and Joe Ciaffoni as CEO bring valuable skills, experiences, and perspectives to the Board, contributing to its effective oversight and decision-making.



The reduction in the size of the Board to seven directors is expected to result in a more streamlined decision-making process, with fewer directors involved in discussions and votes. This could potentially lead to faster decision-making and a more focused approach to strategic planning and execution. However, it is important to note that the effectiveness of this change will depend on the skills, experience, and diversity of the remaining directors, as well as their ability to work together effectively.

In conclusion, Indivior's recent changes to its Board of Directors align with the company's strategic objectives and long-term growth plans, enhancing its governance, operational leadership, and alignment with shareholder interests. The appointments of Dr. David Wheadon as Chair, Daniel Ninivaggi as an Independent Non-Executive Director, and Joe Ciaffoni as CEO bring valuable skills, experiences, and perspectives to the Board, contributing to its effective oversight and decision-making. The reduction in the size of the Board to seven directors is expected to result in a more streamlined decision-making process, with fewer directors involved in discussions and votes.